Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
Editas Medicine (Nasdaq: EDIT) announced promising results from a pre-clinical study of EDIT-301, a gene therapy aimed at treating sickle cell disease. The study showcased a high editing efficiency of approximately 90% in both in vitro and in vivo settings. Additionally, red blood cells derived from EDIT-301 demonstrated over 50% fetal hemoglobin (HbF) expression and significant improvements in cell deformability, indicating potential clinical benefits. The company aims to file an IND for EDIT-301 by the year's end, marking a pivotal step in its development.
Editas Medicine (Nasdaq: EDIT) announced results from a pre-clinical study showcasing the efficacy of its engineered CRISPR-Cas12a technology in iPSC-derived natural killer (iNK) cells for treating solid tumor cancers. The study, presented virtually at the 23rd ASGCT Annual Meeting, demonstrated that edited iNK cells exhibited enhanced tumor-killing activity compared to unedited counterparts. Editas is advancing its oncology programs, including IND-enabling studies for its HDNK engineered cell medicine and collaborations for T cell therapies.
Summary not available.
Summary not available.